cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28776427
title: Pharmacogenomic heterogeneity of <i>N-acetyltransferase 2</i>: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review

description: Isoniazid is primarily metabolized by the arylamine <i>N</i>-acetyltransferase 2 (NAT2) enzyme. Single nucleotide polymorphisms (SNPs) in the <i>NAT2</i> gene could classify an individual into three distinct phenotypes: rapid, intermediate and slow acetylators. <i>NAT2</i> SNPs and the slow acetylator phenotype have been implicated as risk factors for the development of antitubercular drug-induced liver injury (AT-DILI) in several tuberculosis (TB) populations. We conducted a prospective observational study to characterize and compare the <i>NAT2</i> SNPs, genotypes and phenotypes among patients with TB and AT-DILI from the Southern and Western regions of India. The <i>NAT2</i> pharmacogenomic profile of patients from these regions was compared with the reports from several geographically diverse TB populations and participants of different genetic ancestries extracted from literature reviews and the ‘All of Us’ Research Program database, respectively. The TB patients of Southern and Western regions of India and several other geographically closer regions exhibited near similar <i>NAT2</i> MAF characteristics. However significant heterogeneity in <i>NAT2</i> SNPs was observed within and between countries among AT-DILI populations and the participants of different genetic ancestry from the ‘All of Us’ Research Program database. The MAF of the <i>NAT2</i> SNPs rs1041983, rs1801280, rs1799929, rs1799930 and rs1208 of the TB patients from Southern and Western Indian Sites were in near range to that of the South Asian genetic ancestry of ‘All of Us’ Research Program database. About one-third of the total TB patients from the Southern and Western regions of India were <i>NAT2</i> slow acetylators, among whom a relatively higher proportion experienced AT-DILI. Further studies exploring the risk of <i>NAT2</i> SNPs in different AT-DILI patients with larger sample sizes and a population-specific approach are required to establish a policy for <i>NAT2</i> genotyping as a pre-emptive biomarker for AT-DILI monitoring for personalized isoniazid therapy in clinics.
DOI: 10.6084/m9.figshare.28776427.v1
title: Pharmacogenomic heterogeneity of <i>N-acetyltransferase 2</i>: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review

description: Isoniazid is primarily metabolized by the arylamine <i>N</i>-acetyltransferase 2 (NAT2) enzyme. Single nucleotide polymorphisms (SNPs) in the <i>NAT2</i> gene could classify an individual into three distinct phenotypes: rapid, intermediate and slow acetylators. <i>NAT2</i> SNPs and the slow acetylator phenotype have been implicated as risk factors for the development of antitubercular drug-induced liver injury (AT-DILI) in several tuberculosis (TB) populations. We conducted a prospective observational study to characterize and compare the <i>NAT2</i> SNPs, genotypes and phenotypes among patients with TB and AT-DILI from the Southern and Western regions of India. The <i>NAT2</i> pharmacogenomic profile of patients from these regions was compared with the reports from several geographically diverse TB populations and participants of different genetic ancestries extracted from literature reviews and the ‘All of Us’ Research Program database, respectively. The TB patients of Southern and Western regions of India and several other geographically closer regions exhibited near similar <i>NAT2</i> MAF characteristics. However significant heterogeneity in <i>NAT2</i> SNPs was observed within and between countries among AT-DILI populations and the participants of different genetic ancestry from the ‘All of Us’ Research Program database. The MAF of the <i>NAT2</i> SNPs rs1041983, rs1801280, rs1799929, rs1799930 and rs1208 of the TB patients from Southern and Western Indian Sites were in near range to that of the South Asian genetic ancestry of ‘All of Us’ Research Program database. About one-third of the total TB patients from the Southern and Western regions of India were <i>NAT2</i> slow acetylators, among whom a relatively higher proportion experienced AT-DILI. Further studies exploring the risk of <i>NAT2</i> SNPs in different AT-DILI patients with larger sample sizes and a population-specific approach are required to establish a policy for <i>NAT2</i> genotyping as a pre-emptive biomarker for AT-DILI monitoring for personalized isoniazid therapy in clinics.
DOI: 10.6084/m9.figshare.28684646
title: Long-term alveolar-capillary diffusion impairments after severe SARS-CoV-2 pneumonia

description: Persistent respiratory symptoms and impaired gas exchange are common in patients recovering from COVID-19 pneumonia. The Lung Diffusing Capacity for Carbon Monoxide (DLCO) and Carbon Monoxide Transfer Coefficient (KCO) do not adequately distinguish alveolar membrane dysfunction from vascular abnormalities. This study aimed to characterize persistent diffusion impairment in post-ICU patients with prior SARS-CoV-2 pneumonia and reduced DLCO. After hospital discharge, patients underwent spirometry, DLCO measurement, and a 6-minute walking test every six months. If DLCO remained impaired at 18–24 months, a combined Lung Diffusing Capacity for Nitric Oxide (DLNO) and DLCO assessment was performed to differentiate alveolar-capillary membrane (DmCO) and pulmonary capillary blood volume (Vc) alterations. Among 20 patients with persistent DLCO reduction, 3 had an obstructive ventilatory pattern, 6 had restriction, and 12 had low KCO. In restrictive cases, KCO was reduced but remained within normal limits without compensation. The DLNO/DLCO ratio exceeded 113.5% predicted in all patients. DmCO was impaired in 7 patients, while Vc was reduced in 16. Both DLCO determinants were affected, with vascular impairment predominating. Vc reduction was present in most patients, with mean values below the lower limit of normality, whereas DmCO was less affected and often normal. The elevated DLNO/DLCO ratio suggests that persistent DLCO reduction is primarily driven by prolonged pulmonary capillary circulation dysfunction rather than alveolar membrane alterations, highlighting the vascular component as the primary site of long-term impairment.
DOI: 10.6084/m9.figshare.28684646.v1
title: Long-term alveolar-capillary diffusion impairments after severe SARS-CoV-2 pneumonia

description: Persistent respiratory symptoms and impaired gas exchange are common in patients recovering from COVID-19 pneumonia. The Lung Diffusing Capacity for Carbon Monoxide (DLCO) and Carbon Monoxide Transfer Coefficient (KCO) do not adequately distinguish alveolar membrane dysfunction from vascular abnormalities. This study aimed to characterize persistent diffusion impairment in post-ICU patients with prior SARS-CoV-2 pneumonia and reduced DLCO. After hospital discharge, patients underwent spirometry, DLCO measurement, and a 6-minute walking test every six months. If DLCO remained impaired at 18–24 months, a combined Lung Diffusing Capacity for Nitric Oxide (DLNO) and DLCO assessment was performed to differentiate alveolar-capillary membrane (DmCO) and pulmonary capillary blood volume (Vc) alterations. Among 20 patients with persistent DLCO reduction, 3 had an obstructive ventilatory pattern, 6 had restriction, and 12 had low KCO. In restrictive cases, KCO was reduced but remained within normal limits without compensation. The DLNO/DLCO ratio exceeded 113.5% predicted in all patients. DmCO was impaired in 7 patients, while Vc was reduced in 16. Both DLCO determinants were affected, with vascular impairment predominating. Vc reduction was present in most patients, with mean values below the lower limit of normality, whereas DmCO was less affected and often normal. The elevated DLNO/DLCO ratio suggests that persistent DLCO reduction is primarily driven by prolonged pulmonary capillary circulation dysfunction rather than alveolar membrane alterations, highlighting the vascular component as the primary site of long-term impairment.
DOI: 10.6084/m9.figshare.29003804
title: Painkiller administration after endoscopic submucosal dissection surgery: a retrospective real-world study

description: This study aimed to investigate the frequency of analgesic administration within 48 h after endoscopic submucosal dissection (ESD) or its derivative techniques across different segments of the digestive tract, as well as the timing of the initial analgesic administration. This retrospective observational study was built upon previous research. The primary outcomes assessed were the time to initial analgesic administration postoperatively and the frequency of analgesic use within 48 h after ESD surgery. Additionally, factors influencing painkiller administration in ESD patients were analyzed. Of the 2162 patients included in the study, 570 (26.36%) required postoperative analgesic medications. Most patients required their initial analgesic within 8 h following ESD, with the highest demand observed within 2 h. Multivariate Cox regression analysis indicated that intraoperative administration of ketorolac reduced the likelihood of analgesic administration within 2 h postoperatively (hazard ratio [HR] = 0.35, 95% confidence interval [CI]: 0.15–0.79, <i>p</i> = 0.012). The time to first analgesic administration did not differ significantly among patients with varying surgical sites (<i>H</i> = 2.043, <i>p</i> = 0.843) or surgical methods (<i>H</i> = 8.647, <i>p</i> = 0.071). Similarly, no significant difference was observed in the frequency of analgesic use within 48 h across different surgical sites (<i>H</i> = 3.817, <i>p</i> = 0.576). However, patients who underwent endoscopic submucosal excavation (ESE) surgery exhibited a lower frequency of analgesic use compared to those who underwent endoscopic full-thickness resection (EFR) surgery (<i>p</i> = 0.038). A subset of patients undergoing ESD exhibited a need for analgesics within the initial 48-hour postoperative period. Clinicians should carefully assess patients’ pain needs and implement appropriate pain relief measures to improve postoperative outcomes. Chinese Clinical Trial Registry; ChiCTR2300072854
DOI: 10.6084/m9.figshare.29003804.v1
title: Painkiller administration after endoscopic submucosal dissection surgery: a retrospective real-world study

description: This study aimed to investigate the frequency of analgesic administration within 48 h after endoscopic submucosal dissection (ESD) or its derivative techniques across different segments of the digestive tract, as well as the timing of the initial analgesic administration. This retrospective observational study was built upon previous research. The primary outcomes assessed were the time to initial analgesic administration postoperatively and the frequency of analgesic use within 48 h after ESD surgery. Additionally, factors influencing painkiller administration in ESD patients were analyzed. Of the 2162 patients included in the study, 570 (26.36%) required postoperative analgesic medications. Most patients required their initial analgesic within 8 h following ESD, with the highest demand observed within 2 h. Multivariate Cox regression analysis indicated that intraoperative administration of ketorolac reduced the likelihood of analgesic administration within 2 h postoperatively (hazard ratio [HR] = 0.35, 95% confidence interval [CI]: 0.15–0.79, <i>p</i> = 0.012). The time to first analgesic administration did not differ significantly among patients with varying surgical sites (<i>H</i> = 2.043, <i>p</i> = 0.843) or surgical methods (<i>H</i> = 8.647, <i>p</i> = 0.071). Similarly, no significant difference was observed in the frequency of analgesic use within 48 h across different surgical sites (<i>H</i> = 3.817, <i>p</i> = 0.576). However, patients who underwent endoscopic submucosal excavation (ESE) surgery exhibited a lower frequency of analgesic use compared to those who underwent endoscopic full-thickness resection (EFR) surgery (<i>p</i> = 0.038). A subset of patients undergoing ESD exhibited a need for analgesics within the initial 48-hour postoperative period. Clinicians should carefully assess patients’ pain needs and implement appropriate pain relief measures to improve postoperative outcomes. Chinese Clinical Trial Registry; ChiCTR2300072854
DOI: 10.6084/m9.figshare.30919141
title: 3D printing technology in hepatobiliary surgery education: a systematic review

description: Three-dimensional printing (3DP) is increasingly applied in surgical training; however, its effectiveness and reliability in hepatobiliary surgery education remain uncertain. To systematically review the literature on the application and effectiveness of 3DP in hepatobiliary surgical training and anatomical education. PubMed, Embase and the Cochrane Library were searched for publications dated 1 January 1995, to 19 January 2025. Two investigators independently performed the literature search and screened eligible studies that reported the use of 3DP models for surgical training or anatomical education. Study quality was assessed using the Medical Education Research Study Quality Instrument (MERSQI), and levels of evidence were graded using the Oxford Centre for Evidence-Based Medicine (OCEBM) framework. Extracted data included study design, participant numbers, type of surgical training, type of anatomical education, and reported subjective and objective outcomes. Twenty-two studies investigated the application of 3DP in clinical surgical training and 12 studies focused on anatomical education. Laparoscopic procedures were the most frequently reported training context (59%). In anatomical education, tumor localization was the most common task (50%). Ten studies reported that 3DP significantly improved operative performance, reducing operation time by 34–54.6% in laparoscopic and choledochoscopic training. In anatomical education, 3DP models improved students’ performance by 57–70% in liver segment memorization. 3DP models demonstrated substantial value in both surgical training and anatomical education for hepatobiliary surgery. Although still developing, 3DP has already achieved broad acceptance among surgeons and medical students as an effective adjunct for skill acquisition and anatomical understanding. 3DP models are applied in both surgical training and anatomical education, demonstrating broad educational value in hepatobiliary surgery.3DP models significantly shorten operation time and improve surgical skills in hepatobiliary training.In anatomical education, 3DP models enhance tumor localization and outperform CT/VR models. 3DP models are applied in both surgical training and anatomical education, demonstrating broad educational value in hepatobiliary surgery. 3DP models significantly shorten operation time and improve surgical skills in hepatobiliary training. In anatomical education, 3DP models enhance tumor localization and outperform CT/VR models.
DOI: 10.6084/m9.figshare.30919141.v1
title: 3D printing technology in hepatobiliary surgery education: a systematic review

description: Three-dimensional printing (3DP) is increasingly applied in surgical training; however, its effectiveness and reliability in hepatobiliary surgery education remain uncertain. To systematically review the literature on the application and effectiveness of 3DP in hepatobiliary surgical training and anatomical education. PubMed, Embase and the Cochrane Library were searched for publications dated 1 January 1995, to 19 January 2025. Two investigators independently performed the literature search and screened eligible studies that reported the use of 3DP models for surgical training or anatomical education. Study quality was assessed using the Medical Education Research Study Quality Instrument (MERSQI), and levels of evidence were graded using the Oxford Centre for Evidence-Based Medicine (OCEBM) framework. Extracted data included study design, participant numbers, type of surgical training, type of anatomical education, and reported subjective and objective outcomes. Twenty-two studies investigated the application of 3DP in clinical surgical training and 12 studies focused on anatomical education. Laparoscopic procedures were the most frequently reported training context (59%). In anatomical education, tumor localization was the most common task (50%). Ten studies reported that 3DP significantly improved operative performance, reducing operation time by 34–54.6% in laparoscopic and choledochoscopic training. In anatomical education, 3DP models improved students’ performance by 57–70% in liver segment memorization. 3DP models demonstrated substantial value in both surgical training and anatomical education for hepatobiliary surgery. Although still developing, 3DP has already achieved broad acceptance among surgeons and medical students as an effective adjunct for skill acquisition and anatomical understanding. 3DP models are applied in both surgical training and anatomical education, demonstrating broad educational value in hepatobiliary surgery.3DP models significantly shorten operation time and improve surgical skills in hepatobiliary training.In anatomical education, 3DP models enhance tumor localization and outperform CT/VR models. 3DP models are applied in both surgical training and anatomical education, demonstrating broad educational value in hepatobiliary surgery. 3DP models significantly shorten operation time and improve surgical skills in hepatobiliary training. In anatomical education, 3DP models enhance tumor localization and outperform CT/VR models.
DOI: 10.6084/m9.figshare.30876457
title: LBX2-AS1 in acceleration of glycolysis and cancer angiogenesis via miR-491-5p/MDK signaling axis in colorectal cancer: an experimental study

description: Recent studies have identified various roles for long non-coding RNAs (lncRNAs) in cancer progression. However, an in-depth understanding of the regulatory mechanisms of lncRNAs in colorectal cancer (CRC) and their diagnostic significance is rather limited. The diagnostic value of LBX2 antisense RNA 1 (LBX2-AS1) was assessed using public databases and clinical samples. Cell-counting kit 8 (CCK-8), Colony Formation, transwell, and wound scratch assays were performed to assess CRC cell proliferation and metastasis <i>in vitro</i>. Glucose consumption, lactate production, adenosine triphosphate (ATP), extracellular acidification rate (ECAR), and oxygen composition rate (OCR) were evaluated in CRC cells. A dual luciferase assay was used to verify the target-binding relationship of LBX2-AS1/microRNA (miR)-491-5p/midkine (MDK). BALB/C nude mice were used to establish a subcutaneous xenograft mouse model. The role of the LBX2-AS1/MDK axis in CRC proliferation and angiogenesis was analyzed <i>in vivo</i>. As a marker of poor prognosis, LBX2-AS1 was highly expressed in CRC tumor tissues and cells (all <i>p</i> &lt; 0.01). Downregulation of LBX2-AS1 inhibited the proliferation, migration, and invasion of CRC cells (all <i>p</i> &lt; 0.01). Furthermore, the levels of glucose consumption, lactate production, ATP, ECAR, glycolytic-related indicators, and markers of angiogenesis were also inhibited by the downregulation of LBX2-AS2 expression (all <i>p</i> &lt; 0.01). Overexpression of MDK reversed the downregulation of LBX2-AS1 inhibition of these biological activities in CRC cells (all <i>p</i> &lt; 0.01). Downregulation of LBX-AS1 inhibited tumor growth and angiogenesis <i>in vivo</i> (all <i>p</i> &lt; 0.001). Overexpression of MDK reversed the downregulation of LBX2-AS1 inhibition of tumor growth and angiogenesis <i>in vivo</i> (all <i>p</i> &lt; 0.001). Mechanistically, LBX2-AS1 regulated MDK transcription by mediating miR-491-5p. This study demonstrates that LBX2-AS1 promotes CRC angiogenesis and activates the glycolysis <i>via</i> the miR-491-5p/MDK axis. LBX2-AS may serve as a novel diagnostic biomarker and potential therapeutic target for CRC.
DOI: 10.6084/m9.figshare.30876457.v1
title: LBX2-AS1 in acceleration of glycolysis and cancer angiogenesis via miR-491-5p/MDK signaling axis in colorectal cancer: an experimental study

description: Recent studies have identified various roles for long non-coding RNAs (lncRNAs) in cancer progression. However, an in-depth understanding of the regulatory mechanisms of lncRNAs in colorectal cancer (CRC) and their diagnostic significance is rather limited. The diagnostic value of LBX2 antisense RNA 1 (LBX2-AS1) was assessed using public databases and clinical samples. Cell-counting kit 8 (CCK-8), Colony Formation, transwell, and wound scratch assays were performed to assess CRC cell proliferation and metastasis <i>in vitro</i>. Glucose consumption, lactate production, adenosine triphosphate (ATP), extracellular acidification rate (ECAR), and oxygen composition rate (OCR) were evaluated in CRC cells. A dual luciferase assay was used to verify the target-binding relationship of LBX2-AS1/microRNA (miR)-491-5p/midkine (MDK). BALB/C nude mice were used to establish a subcutaneous xenograft mouse model. The role of the LBX2-AS1/MDK axis in CRC proliferation and angiogenesis was analyzed <i>in vivo</i>. As a marker of poor prognosis, LBX2-AS1 was highly expressed in CRC tumor tissues and cells (all <i>p</i> &lt; 0.01). Downregulation of LBX2-AS1 inhibited the proliferation, migration, and invasion of CRC cells (all <i>p</i> &lt; 0.01). Furthermore, the levels of glucose consumption, lactate production, ATP, ECAR, glycolytic-related indicators, and markers of angiogenesis were also inhibited by the downregulation of LBX2-AS2 expression (all <i>p</i> &lt; 0.01). Overexpression of MDK reversed the downregulation of LBX2-AS1 inhibition of these biological activities in CRC cells (all <i>p</i> &lt; 0.01). Downregulation of LBX-AS1 inhibited tumor growth and angiogenesis <i>in vivo</i> (all <i>p</i> &lt; 0.001). Overexpression of MDK reversed the downregulation of LBX2-AS1 inhibition of tumor growth and angiogenesis <i>in vivo</i> (all <i>p</i> &lt; 0.001). Mechanistically, LBX2-AS1 regulated MDK transcription by mediating miR-491-5p. This study demonstrates that LBX2-AS1 promotes CRC angiogenesis and activates the glycolysis <i>via</i> the miR-491-5p/MDK axis. LBX2-AS may serve as a novel diagnostic biomarker and potential therapeutic target for CRC.